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lementing genes for retroviral proteins and retroviral vector In the 9L rat model, G418
R cell cultures were only obtained RNAs can be used for in situ transduction of target cells. when 9L cells were harvested from tumors injected with Keywords: adenovirus; retrovirus; gene therapy There have been several recent reports describing the use of recombinant viruses of one species to provide transcomplementing functions which support the amplification of replication-deficient variants of a second viral species. [1] [2] [3] [4] [5] [6] [7] [8] These reports have primarily been in vitro studies which demonstrate the principle that virusmediated provision of these transcomplementing functions is adequate to support the generation of a second vector. Feng and co-workers 7 although have reported evidence that this can occur in vivo using an adeno-retroviral hybrid system. 7 The system, consisting of two adenoviruses, one carrying a retroviral transcription unit encoding green fluorescent protein (GFP) and a second expressing retroviral gag.pol and env functions, was used to transduce human ovarian tumor cells (SKOV3. p1 ) in vivo. Co-injection of both adenoviruses resulted in more efficient transduction of the tumor compared with administration of the adenovirus carrying the retroviral GFP vector alone. To examine further the potential appli-cation of this type of system in vivo we have developed a similar hybrid viral system consisting of four adenoviruses encoding: (1) gag.pol from Moloney murine leukemia virus (MoMLV) (Axtet.gag.pol); (2) envelope from vesicular stomatitis virus-G (VSV-G) (Axtet.VSV-G); (3) LXSN (AV-LXSN) which contains the neomycin phosphotransferase (neo) gene; and (4) a doxycyclinedependent transactivator (tTA) (AV-rtTA) to regulate expression of the gag.pol and envelope transcription units. Here we report the efficiency of LXSN integration and the extent to which neo gene expression results from proviral integration via normal mammalian type C oncornaviral pathways as opposed to episomal maintenance of the adenoviral vector.
We first assessed the ability of the transcomplementing adeno-retroviral vectors to generate LXSN retrovirus in rat 9L glioma cells in vitro. Using different multiplicities of infection (MOI) of each virus (see Table 1 ), 1 × 10 6 9L cells were transduced for 24 h, after which the cells were washed with growth media supplemented with pooled human serum ␥-globulin (1 g/ml) as a source of neutralizing antibody against adenovirus. The washes significantly reduce carry over of residual adenoviral vectors in newly synthesized retroviral supernatants. 8 Growth media supplemented with human serum The construction of AV-LXSN, Axtet.gag.pol, and Axtet.VSV-G have been reported elsewhere. 8, 14, 15 The transactivating vector, AV-rtTA was constructed by introducing a 1.2 kb cDNA of the reverse phenotype tetracycline transactivator 16 into the adenovirus shuttle plasmid pAVC2. 8 The resulting plasmid (pAV-rtTA) was cotransfected with pJM17 into 293 cells via calcium phosphate precipitation and the adenovirus plaque purified, amplified and titrated by standard techniques. 17, 18 Rat 9L gliosarcoma cells (a gift of E Oldfield, NINDS, NIH) were plated at a density of 1 × 10 6 in T75 flasks in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS) and 50.0 g/ml gentamicin sulfate and grown overnight. Adenoviruses were added to target cells in a minimal volume of medium at the MOIs shown in Table 1 . After 4-6 h additional medium was added. Twenty-four hours after initiation of transduction cells were washed five times with DMEM supplemented with 1 mg/ml human serum ␥-globulin (Miles Research Products Division, Elkhart, IN, USA) to a final concentration of 1 g/ml. Growth medium supplemented with human serum ␥-globulin (1 g/ml) plus or minus 1 m doxycycline was added to each flask and supernatants harvested at the time-periods shown in Table 2 . Supernatants were centrifuged at 700 g, 4°C, filtered (0.45 m), aliquoted and stored at −80°C. For retroviral transduction of target cells, TE671 cells were plated in six-well plates at 5 × 10 4 cells per well and incubated overnight at 37°C/10% CO 2 . Transductions were conducted at 37°C in duplicate by plating 2 ml of undiluted or serially diluted viral supernatant supplemented with polybrene (8 g/ml) on to TE671 cells. After overnight incubation, the inoculum was replaced by fresh growth medium supplemented with 1 mg/ml G418 (Life Technologies). Cells were grown for 12-14 days in the presence of G418 (1 mg/ml) with changes of medium every 3-4 days.
␥-globulin (1 g/ml) were added to each flask. Supernatants were harvested at 48 h after adenoviral transduction in all cases and, in one experiment, following addition of further media after an additional 24 h. Supernatants were titered on TE671 cells as previously described 8 ( Table 1 To confirm that G418 R results from integration of proviral sequences derived from the retroviral particles produced via transcomplementation with the four adenoviruses, Southern blot analysis was conducted on high molecular weight DNA from expanded populations of the transduced TE671 cells as previously described 8 ( Figure 1a ). The adenoviral vector AV-LXSN contains a single XbaI restriction site in the 3Ј LTR sequence. Retroviral integration resulting from reverse transcription of LXSN genomic RNA results in duplication of the 3Ј LTR U3 sequence to form the 5Ј LTR U3 sequence of the proviral integrant. Digestion of retrovirally integrated provirus with XbaI should result in a single fragment of 2.7 kb, whereas episomally carried AV-LXSN DNA would be detected as a 3.5 kb fragment. In addition, KpnI should cleave all proviral sequences twice, once in each sequence, independently of whether it is a chromosomally integrated proviral sequence or episomally carried in the adenoviral vector. Comparison of the intensity of the 2.7 kb KpnI and XbaI bands serve further to confirm the origin of the neo hybridization signal. A unique 2.7 kb XbaI neo containing fragment was observed in DNA from TE671 cells transduced with supernatants derived from the transduction of rat 9L glioma cells with the full set of transcomplementing adeno-retroviral vectors ( Figure  1a , lane 6). The intensity of the neo hybridization signal seen following digestion of the same DNA with XbaI was the same as that seen following digestion with KpnI confirming that all of the G418 R seen can be accounted for by LXSN proviral integration (Figure 1a , lanes 5 and 6). These observations are consistent with normal retrovirus reverse transcription and integration as shown by transduction of TE671 cells with supernatants obtained by AV-LXSN transduction of GP+E86 and FLYA13 retroviral vector packaging cell lines (Figure 1a, lanes 7-10) .
To assess the feasibility of applying this system in vivo, rat 9L glioma cells were used to establish subcutaneous tumors in rats, and direct intratumoral injections of all four test adenoviruses, or AV-LXSN alone, were performed. Those animals receiving all four viruses were further divided into two groups with one group being given doxycycline via their drinking water. Tumors were harvested from two animals in each group 120 h after adenovirus injection and dissociated by enzymatic digestion. Cells were harvested, counted and then plated at decreasing densities. After 24 h, G418 was added to the growth medium (Table 2) . G418-resistant colonies were only generated from cells harvested from rat 9L glioma cells transduced with all four transcomplementing adeno-retroviruses. No G418 R colonies were obtained from tumors injected with AV-LXSN alone. As was seen previously in vitro, these observations are indicative of the in vivo generation of retroviral particles in rat 9L glioma cells transduced with the transcomplementing adeno-retroviral vectors. The number of G418-resistant clones obtained indicate a relatively low transduction frequency but is consistent with the poor efficiency with which rodent cells are transduced by adenovirus, particularly in tumors transduced via direct injection (transduction less than 10%; WJ Ramsey, unpublished data).
Molecular analysis was conducted to examine the integrative process which had occurred to generate the G418 resistance observed (Figure 1b) . Cells harvested from an animal in group 1, which received all four transcomplementing adeno-retroviruses (AV-LXSN, Axtet.gag.pol, Axtet.VSV-G and AV-rtTA) and doxycycline showed generation of the appropriate integrated retroviral sequence, a 2.7 kb XbaI fragment (Figure 1b, lane 5) . The relative intensity of the XbaI and KpnI neo containing fragments was equal, indicating that all of the G418 resistance observed can be attributed to LXSN proviral integration (Figure 1b, lanes 5 and 6) . In contrast, cells harvested from a group 2 animal which received all four transcomplementing viruses, but not doxycycline, showed evidence of episomally maintained adenoviral sequences as indicated by the presence of a 3.5 kb XbaI fragment (Figure 1b, lane 8) .
We also assessed this system in a second tumor model using immunodeficient animals. Subcutaneous tumors were generated in athymic nude mice using the human melanoma cell line A375. 9, 10 The initial retroviral transduction efficiency, as judged by the number of G418-resistant colonies rescued from the tumor mass, was similar to that seen in the 9L tumor model ( Figure 2) ; however, in this model we took the opportunity to follow the extent of retroviral transduction over time. At subsequent time-points (weeks 3 and 4 after injection) a much higher frequency of transduction was observed ( Figure 2) ; at week 4 up to 7.2% of cells were retrovirally transduced. As would be expected in an athymic nude mouse model, elimination of the adenoviral vector AV-LXSN was not seen in the time-frame we examined and the level of G418-resistant colonies obtained from animals treated with AV-LXSN alone remained relatively constant during the time-period studied. The higher level of G418-resistant colonies seen initially from AV-LXSN tumors alone, as compared with tumors receiving all four adenoviruses, 
AV-LXSN Ͻ1
Rat glioma 9L cells were used to establish subcutaneous tumors as described elsewhere. 19 Briefly, 9L cells were grown in DMEM supplemented with 10% FBS and 50.0 g/ml gentamicin sulfate. Cells were trypsinized, rinsed twice with PBS and re-suspended in Hank's buffered salt solution at a density of 3 × 10 7 cells/ml. Tumors were placed on the right flank of female F344 rats (DCT.NCI, Frederick, MD, USA) by injection of 3 × 10 6 cells using a tuberculin syringe and a 25-gauge needle. Tumors were permitted to reach approximately 150 mm 3 before injection with virus. Tumors were injected with recombinant adenoviruses in a total volume of 100 l. Three groups of animals received injections of recombinant adenoviruses: group 1 received AV-LXSN, Axtet.gag.pol, Axtet.VSV-G and AV-rtTA (2 × 10 9 p.f.u. total, 5 × 10 8 of each virus) and doxycycline (as a 10 mg/ml solution in 5% sucrose via their water bottles) for a period of 3 days starting at 24 h after injection; group 2 received AV-LXSN, Axtet.gag.pol, Axtet.VSV-G and AV-rtTA (2 × 10 9 p.f.u. total, 5 × 10 8 of each virus); and group 3 (control) animals were given 5 × 10 8 p.f.u. of AV-LXSN alone. Tumors were harvested from two animals in each group at 120 h after injection and subjected to dissociation by incubation in triple enzyme solution (0.1% collagenase type IV, 0.002% deoxyribonuclease type IV and 0.01% hyaluronidase type V) 20 for 30 min at room temperature. Harvested cells were washed twice in PBS, viable cells were counted by trypan blue exclusion and then aliquoted (10 6 , 10 5 , 10 4 , 10 3 or 10 2 cells per well) into six-well plates containing DMEM supplemented with 10% FBS and 4 g/ml Fungizone (Life Technologies); cells from each tumor were plated separately. After 24 h, growth medium was replaced with growth medium supplemented with 1 mg/ml G418. Cells were grown for 14 days in the presence of G418 (1 mg/ml) with changes of medium every 3-4 days. All animal care and procedures were in compliance with AALAC and NIH guidelines. Results are expressed as the number of G418 R colonies observed after selection per 10 6 plated cells.
is probably related to the cytotoxicity associated with expression of VSV-G (J Higginbotham, unpublished observation). Molecular analysis was conducted on the harvested A375 cell populations after at least 21 days in culture. Figure 3 shows the Southern analysis of DNA purified from populations derived from tumors harvested 3 and 4 weeks after administration of virus. Retrovirally integrated proviral sequences were not detected in animals which received AV-LXSN alone (as indicated by the absence of a 2.7 kb XbaI fragment, Figure 3a , lane 12 and Figure 3b , lane 12); G418 resistance in these populations appears to be a result of low level episomal adenoviral persistence, suggested by the presence of a 2.7 kb KpnI fragment representing total LXSN DNA (Figure 3a , lane Table 2 11) or random integration. Randomly integrated AV-LXSN fragments could be seen as generalized hybridization to high molecular weight DNA from the these animals ( Figure 3b, lane 12) . In contrast, the LXSN proviral sequence was seen in cells harvested from all animals which received all four transcomplementing adeno-retroviruses ( Figure 3a , lanes 6, 8 and 10 and 3b, lanes 6, 8 and 10). The relative intensity of the XbaI and KpnI neo containing fragments were equivalent indicating that all of the G418 resistance observed can be attributed to LXSN proviral integration in these groups (Figure 3a , lanes 5 and 6, lanes 7 and 8 and lanes 9 and 10; Figure  3b lanes 5 and 6, lanes 7 and 8 and lanes 9 and 10). Interestingly, neither the percentage of G418-resistant colonies obtained nor the presence of the LXSN proviral sequence was affected by treatment with doxycycline. There may be several reasons for this observation: (1) the presence of the adenoviral E1a enhancer near the synthetic promoter containing the tet operator sites perhaps causes an elevated level of transcription despite the absence of the transcriptional transactivator; (2) there may be some degree of adenoviral vector DNA replication occurring in A375 cells which significantly increases template number, as reported for other human tumor cells; 11 or (3) this is due to the effects of high concentrations of input virus and/or more efficient uptake of injected virus than was seen in the rat 9L glioma model. Each of these could potentially override the tetracycline sensitivity of this system, particularly in human cells, accounting for why this was not seen in the rat model. Preliminary in vitro experiments confirm that at high doses of input adenovirus in human cells, diminishment of doxycycline sensitivity occurs; at MOIs of 10-30 an approximate 2000-fold induction with doxycycline is seen whereas at MOIs of 100-300 only a 13-fold induction with doxycycline is seen. Additionally, total retroviral production decreases 100-fold in the presence of excessive input adenovirus (J Higginbotham, unpublished data).
The potential application of these hybrid viral systems to gene therapy will be determined by the extent to which they surpass or complement existing gene transfer strategies. The in vivo use of retroviral vector producer cells has been reported by numerous groups as a means of increasing the gene transfer efficiency of retroviral vectors to tumors 12 and has been the foundation for a least one human clinical trial. 13 The principal limitations reportedly associated with this approach relate to poor distribution of vector producer cells (in situ hybridization analysis of human tumors injected with retroviral vector producer cells showed only small clusters of positive cells limited to within a few cell layers around the injection tract 13 ) and the rapid complement-mediated inactivation of these xenografted cells and the vectors they produce outside of the 'immune privileged' central nervous system. Adenoviral vectors have extremely high titers, a broad host range, and the ability to infect and express in nondividing cells. It is probable that adenovirally transduced host cells will be subject to a significantly slower immune clearance than that seen with xenogeneic retrovirus-producer cells. However, cellular regeneration as a consequence of adenoviral cytotoxicity or immune clearance should still be of adequate magnitude to create a population of dividing target cells competent for successful transduction by in situ generated retrovirus. In addition, adenoviral vectors are much simpler biologically than retroviral vector producer cell lines and thus the types of hybrid vector described here will be easier to produce for clinical application. These reasons justify exploring the use of adenoviruses expressing essential retroviral components as an alternative mechanism for delivering retroviruses in vivo.
The study presented here expands upon the work of Feng et al, 7 demonstrating by molecular means that retroviral vector production and proviral integration occurs in vivo. We have reported previously that the re-duplication of the 3Ј long terminal repeat (LTR) sequence, typical of retrovirus-mediated reverse transcription and integration, occurs when secondary retrovirus produced in this system transduces new target cells. 8 In the experiments described here we demonstrate this characteristic reduplication of 3Ј LTR sequences to the 5Ј LTR during proviral LXSN DNA integration in vivo, as opposed to episomal maintenance of adenoviral DNA. Initially, only low levels of transduction were seen as judged by resistance to G418 but this increased with time, as would be expected if there was subsequent transduction with retrovirus produced in situ. The study of Feng and coworkers 7 reported slightly higher frequency of transduction. There are several possible reasons for this including: (1) the use of only two transcomplementing viruses; and (2) intraperitoneal tumor models may provide chimeric viruses greater access to target tissues as opposed to transduction of solid subcutaneous tumors.
In our current model, the necessity of transducing tar-
